Berthelot-Richer Maxime, O'Connor Kim, Bernier Mathieu, Trahan Sylvain, Couture Christian, Dubois Michelle, Sénéchal Mario
Department of Cardiology, Institut universitaire de cardiologie et de pneumologie de Québec, Laval University, Québec, Canada.
Exp Clin Transplant. 2014 Dec;12(6):565-8. doi: 10.6002/ect.2013.0218. Epub 2014 Mar 19.
Giant cell myocarditis is a rare and often fatal disorder. According to the American Heart Association, the American College of Cardiology Foundation, and the European Society of Cardiology scientific statements, an endomyocardial biopsy should be done to exclude giant cell myocarditis in unexplained new-onset heart failure of 2 weeks to 3 months duration associated with dilated left ventricle and new ventricular arrhythmias, or Mobitz type II second-degree, or third-degree atrioventricular heart block.
Two hundred thirty-five heart transplants were performed since May 1993 at the Institut universitaire de cardiologie et de pneumologie de Quebec, Canada. Giant cell myocarditis was found in the explanted hearts of 5 patients. The preoperative diagnosis of giant cell myocarditis was done by endomyocardial biopsy or at the installation of a left ventricular-assisted device. Patients had symptoms of progressive heart failure of subacute onset. Patients consulted at a mean 32 days after the onset of symptoms. Two patients neither had ventricular arrhythmia nor heart block. Two patients had ventricular arrhythmias and heart block; the other patient had symptomatic heart block. All patients had at least 2 echocardiographies. Two patients had an increase in left ventricular size, enough to reach the criteria of left ventricular dilatation according to the American Society of Echocardiography. During this time, left ventricular ejection fraction showed a rapid decline (mean 37% to 16%).
Ventricular arrhythmia, heart block, and left ventricular dilatation initially can be absent in many patients having giant cell myocarditis with symptoms of progressive heart failure. Endo-myocardial biopsy should be quickly considered in patients with a rapid and dramatic decline of left ventricular ejection fraction, even in the absence of classic clinical and echocardiographic features of giant cell myocarditis to rapidly obtain the diagnosis of this rare but lethal disease.
巨细胞性心肌炎是一种罕见且通常致命的疾病。根据美国心脏协会、美国心脏病学会基金会以及欧洲心脏病学会的科学声明,对于病程在2周 至3个月、病因不明、新发的伴有左心室扩张及新发室性心律失常,或莫氏Ⅱ型二度或三度房室传导阻滞的心力衰竭患者,应进行心内膜心肌活检以排除巨细胞性心肌炎。
自1993年5月起,加拿大魁北克大学心脏病学与肺病学研究所共进行了235例心脏移植手术。在5例患者的移植心脏中发现了巨细胞性心肌炎。巨细胞性心肌炎的术前诊断通过心内膜心肌活检或在安装左心室辅助装置时做出。患者有亚急性起病的进行性心力衰竭症状。患者在症状出现后平均32天就诊。2例患者既无室性心律失常也无心脏传导阻滞。2例患者有室性心律失常和心脏传导阻滞;另1例患者有症状性心脏传导阻滞。所有患者至少进行了2次超声心动图检查。2例患者左心室大小增加,足以达到美国超声心动图学会规定的左心室扩张标准。在此期间,左心室射血分数迅速下降(平均从37%降至16%)。
许多有进行性心力衰竭症状的巨细胞性心肌炎患者最初可能没有室性心律失常、心脏传导阻滞和左心室扩张。对于左心室射血分数迅速且显著下降的患者,即使没有巨细胞性心肌炎的典型临床和超声心动图特征,也应迅速考虑进行心内膜心肌活检,以便快速诊断这种罕见但致命的疾病。